JP2001502537A - ヒト前立腺ガンの進行の動物モデル - Google Patents
ヒト前立腺ガンの進行の動物モデルInfo
- Publication number
- JP2001502537A JP2001502537A JP10518512A JP51851298A JP2001502537A JP 2001502537 A JP2001502537 A JP 2001502537A JP 10518512 A JP10518512 A JP 10518512A JP 51851298 A JP51851298 A JP 51851298A JP 2001502537 A JP2001502537 A JP 2001502537A
- Authority
- JP
- Japan
- Prior art keywords
- prostate cancer
- xenograft
- cells
- mouse
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 58
- 206010060862 Prostate cancer Diseases 0.000 title claims description 203
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 201
- 238000010171 animal model Methods 0.000 title claims description 5
- 210000002307 prostate Anatomy 0.000 claims abstract description 33
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 261
- 206010028980 Neoplasm Diseases 0.000 claims description 124
- 241000699670 Mus sp. Species 0.000 claims description 103
- 239000003098 androgen Substances 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 61
- 210000001519 tissue Anatomy 0.000 claims description 53
- 206010027476 Metastases Diseases 0.000 claims description 52
- 210000001185 bone marrow Anatomy 0.000 claims description 52
- 238000007920 subcutaneous administration Methods 0.000 claims description 46
- 230000009401 metastasis Effects 0.000 claims description 44
- 230000012010 growth Effects 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 40
- 238000011579 SCID mouse model Methods 0.000 claims description 38
- 210000000988 bone and bone Anatomy 0.000 claims description 33
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 27
- 230000001419 dependent effect Effects 0.000 claims description 26
- 239000006285 cell suspension Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 230000001394 metastastic effect Effects 0.000 claims description 21
- 238000001727 in vivo Methods 0.000 claims description 18
- 210000000963 osteoblast Anatomy 0.000 claims description 16
- 230000001582 osteoblastic effect Effects 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 11
- 210000002303 tibia Anatomy 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 210000001165 lymph node Anatomy 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 238000010998 test method Methods 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 abstract description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 46
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 46
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 238000012360 testing method Methods 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 24
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 24
- 108010080146 androgen receptors Proteins 0.000 description 22
- 102000001307 androgen receptors Human genes 0.000 description 20
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 230000004614 tumor growth Effects 0.000 description 13
- 206010027452 Metastases to bone Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000001574 biopsy Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 208000023958 prostate neoplasm Diseases 0.000 description 8
- 230000005740 tumor formation Effects 0.000 description 8
- 208000018084 Bone neoplasm Diseases 0.000 description 7
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000004088 simulation Methods 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 206010061728 Bone lesion Diseases 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 6
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000002559 cytogenic effect Effects 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 101710121821 Galectin-6 Proteins 0.000 description 4
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 101150052863 THY1 gene Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- ZKUKMWMSYCIYRD-ZXFNITATSA-N lenampicillin Chemical compound O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3N2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C ZKUKMWMSYCIYRD-ZXFNITATSA-N 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010066327 Keratin-18 Proteins 0.000 description 3
- 102000018329 Keratin-18 Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000007479 molecular analysis Methods 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 238000011471 prostatectomy Methods 0.000 description 3
- 210000000614 rib Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007798 limiting dilution analysis Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 230000006510 metastatic growth Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 238000012090 tissue culture technique Methods 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027468 Metastases to spine Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000849798 Nita Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- -1 antisense sequence Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940030749 prostate cancer vaccine Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.局所的に進行した、または転移性のヒト前立腺ガン異種移植片を有する免疫欠 損マウス。 2.局所的に進行した前立腺ガンが段階Cにある、請求項1のマウス。 3.転移性の前立腺ガンが段階Dにある、請求項1のマウス。 4.請求項1のSCIDマウス。 5.異種移植片がアンドロゲン依存性である、請求項1のマウス。 6.異種移植片がアンドロゲン非依存性である、請求項1のマウス。 7.異種移植片がアンドロゲン存在下ではアンドロゲン依存性であり、アンドロゲ ン非存在下ではアンドロゲン非依存性である、請求項1のマウス。 8.異種移植片が前立腺、リンパ節、肺または骨組織から選択された移植片由来で ある、請求項1のマウス。 9.ヒト由来の局所的に進行した、または転移性の前立腺ガン組織、またはその細 胞懸濁液を免疫欠損マウスに移植し、そのように移植された組織を成長させるこ とからなる、マウス中で前立腺ガンと同様にふるまうヒト前立腺ガン異種移植片 を生成する方法。 10.組織が皮下移植される、請求項9の方法。 11.成長した異種移植片を別のマウスに移植して成長させる、請求項9の方法。 12.a.請求項9の方法によって免疫欠損マウス中にヒト前立腺ガン異種移植片を生 成し、b.免疫欠損マウスの移植部位以外で前立腺ガン細胞の検出が可能になるた めに十分な時間異種移植片腫瘍を成長させることからなる、一次腫瘍形成から微 小組織転移までのヒト前立腺ガンの進行を動物モデルでシミュレーションする方 法。 13.a.の異種移植片が皮下移植される、請求項12の方法。 14.a.の異種移植片が前立腺内に移植される、請求項12の方法。 15.検出が免疫欠損マウスの末梢血を用いて行われる、請求項12の方法。 16.検出が免疫欠損マウスの骨髄を用いて行われる場合の、請求項12の方法。 17.a.請求項9の方法により生成した前立腺ガン異種移植片から調製された前立腺 ガン細胞の単一細胞懸濁液を、免疫欠損マウスの脛骨骨髄腔に注射し、b.注射さ れた細胞を成長させて、ヒト前立腺ガンにおける骨芽細胞転移の進行と同様のふ るまいをする骨芽細胞性骨損傷を形成させることからなる、ヒト前立腺ガンにお ける骨芽細胞転移の進行をシミュレーションする方法。 18.請求項9の方法によって作られるSCIDマウス。 19.(a)請求項9の方法によって作られたヒト前立腺ガン異種移植片を皮下に有す る免疫欠損マウスに治療を行い、(b)異種移植片の成長に対する治療の効果を決 定することからなる、ヒト前立腺ガンの治療効果を評価するための試験法。 20.(a)請求項9の方法によって免疫欠損マウスの皮下に前立腺ガン異種移植片を 導入し、(b)in vivoで異種移植片をある遺伝子によって形質転換し、(c)末梢血 、骨髄、リンパ節、または他の皮下異種移植片部位から遠位の部位中の前立腺ガ ン細胞を検出することによって免疫欠損マウス中の微小組織転移の有無を評価す ることからなる、微小組織転移性前立腺ガンの進行に上記遺伝子が与える効果( この効果は、形質導入されていない単離細胞を用いて作られた、ヒト前立腺異種 移植片を皮下に有する対照の免疫欠損マウスとの比較によって決定される)を決 定するための試験法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73267696A | 1996-10-15 | 1996-10-15 | |
US08/732,676 | 1996-10-15 | ||
PCT/US1997/018483 WO1998016628A1 (en) | 1996-10-15 | 1997-10-15 | Animal models of human prostate cancer progression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008173119A Division JP2009017879A (ja) | 1996-10-15 | 2008-07-02 | ヒト前立腺ガンの進行の動物モデル |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001502537A true JP2001502537A (ja) | 2001-02-27 |
Family
ID=24944541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10518512A Pending JP2001502537A (ja) | 1996-10-15 | 1997-10-15 | ヒト前立腺ガンの進行の動物モデル |
JP2008173119A Pending JP2009017879A (ja) | 1996-10-15 | 2008-07-02 | ヒト前立腺ガンの進行の動物モデル |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008173119A Pending JP2009017879A (ja) | 1996-10-15 | 2008-07-02 | ヒト前立腺ガンの進行の動物モデル |
Country Status (9)
Country | Link |
---|---|
US (1) | US6107540A (ja) |
EP (1) | EP0953039B1 (ja) |
JP (2) | JP2001502537A (ja) |
AT (1) | ATE371721T1 (ja) |
AU (1) | AU4818997A (ja) |
CA (1) | CA2271234C (ja) |
DE (1) | DE69738077T2 (ja) |
ES (1) | ES2290964T3 (ja) |
WO (1) | WO1998016628A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526251A (ja) * | 2011-09-07 | 2014-10-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 流体サンプルから回収された標的細胞の数を増大させる方法 |
JP2016021931A (ja) * | 2014-07-22 | 2016-02-08 | 国立大学法人福井大学 | 子宮肉腫転移モデル動物 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053263B2 (en) * | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
ATE437947T1 (de) | 1998-06-01 | 2009-08-15 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
IL142273A0 (en) | 1998-09-30 | 2002-03-10 | Urogenesys Inc | Testis specific proteins expressed in prostate cancer |
EP1792989A1 (en) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
CA2369413C (en) | 1999-04-12 | 2013-07-09 | Agensys, Inc. | Transmembrane protein expressed in prostate and other cancers |
AU774436B2 (en) | 1999-08-12 | 2004-06-24 | Agensys, Inc. | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
FR2797743B1 (fr) * | 1999-08-23 | 2003-08-08 | Urogene | Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal |
IL147952A0 (en) | 1999-10-05 | 2002-08-14 | Agensys Inc | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
ES2323407T3 (es) | 2000-07-12 | 2009-07-15 | Agensys, Inc. | Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon. |
AU8846601A (en) | 2000-08-28 | 2002-03-13 | Agensys Inc | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
JP2005505271A (ja) | 2001-09-06 | 2005-02-24 | アジェンシス, インコーポレイテッド | 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質 |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
US7087371B2 (en) * | 2002-06-28 | 2006-08-08 | The Trustees Of The University Of Pennsylvania | Material and methods for the production of sperm and analysis thereof |
AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
NZ538601A (en) * | 2002-08-29 | 2008-06-30 | Arizona Board Of Regents And O | Animal model for perimenopause and menopause and methods of inducing ovarian failure |
EP2343315A3 (en) | 2003-02-10 | 2011-11-23 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
GB0308150D0 (en) * | 2003-04-09 | 2003-05-14 | Cxr Biosciences Ltd | Method of determining xenograft responses |
ES2384622T3 (es) | 2003-05-30 | 2012-07-10 | Agensys, Inc. | Variantes del antígeno de células madre de próstata (PSCA) y subsecuencias de las mismas |
US20040268421A1 (en) * | 2003-06-30 | 2004-12-30 | Infraredx, Inc. | Animal model for medical device testing and training using xenografted organ structures such as blood vessels |
GB0322196D0 (en) * | 2003-09-23 | 2003-10-22 | Cxr Biosciences Ltd | Excretable reporter systems |
EP1753871B1 (en) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
US7968762B2 (en) * | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
CA2603093A1 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
MX2012008884A (es) | 2010-02-08 | 2012-08-31 | Agensys Inc | Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b. |
US9526911B1 (en) * | 2010-04-27 | 2016-12-27 | Lazure Scientific, Inc. | Immune mediated cancer cell destruction, systems and methods |
US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
EP2689787A1 (en) | 2010-09-03 | 2014-01-29 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
JP6326371B2 (ja) | 2011-11-04 | 2018-05-16 | ザイムワークス,インコーポレイテッド | Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン |
PL2887959T3 (pl) | 2012-08-23 | 2019-04-30 | Agensys Inc | Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7 |
AU2014296219A1 (en) | 2013-08-01 | 2016-02-25 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to CD37 proteins |
JP2017524377A (ja) | 2014-06-20 | 2017-08-31 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | 単一細胞由来オルガノイド |
AU2017360887B2 (en) | 2016-11-17 | 2023-01-19 | Nant Holdings Ip, Llc | Validation of inferred anticancer pathways |
WO2021066869A1 (en) | 2019-10-04 | 2021-04-08 | TAE Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
-
1997
- 1997-10-15 JP JP10518512A patent/JP2001502537A/ja active Pending
- 1997-10-15 AT AT97910929T patent/ATE371721T1/de active
- 1997-10-15 ES ES97910929T patent/ES2290964T3/es not_active Expired - Lifetime
- 1997-10-15 US US08/951,143 patent/US6107540A/en not_active Expired - Lifetime
- 1997-10-15 WO PCT/US1997/018483 patent/WO1998016628A1/en active IP Right Grant
- 1997-10-15 EP EP97910929A patent/EP0953039B1/en not_active Expired - Lifetime
- 1997-10-15 AU AU48189/97A patent/AU4818997A/en not_active Abandoned
- 1997-10-15 CA CA2271234A patent/CA2271234C/en not_active Expired - Lifetime
- 1997-10-15 DE DE69738077T patent/DE69738077T2/de not_active Expired - Lifetime
-
2008
- 2008-07-02 JP JP2008173119A patent/JP2009017879A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526251A (ja) * | 2011-09-07 | 2014-10-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 流体サンプルから回収された標的細胞の数を増大させる方法 |
JP2016021931A (ja) * | 2014-07-22 | 2016-02-08 | 国立大学法人福井大学 | 子宮肉腫転移モデル動物 |
Also Published As
Publication number | Publication date |
---|---|
AU4818997A (en) | 1998-05-11 |
CA2271234A1 (en) | 1998-04-23 |
CA2271234C (en) | 2011-04-26 |
EP0953039A1 (en) | 1999-11-03 |
ATE371721T1 (de) | 2007-09-15 |
US6107540A (en) | 2000-08-22 |
EP0953039B1 (en) | 2007-08-29 |
JP2009017879A (ja) | 2009-01-29 |
EP0953039A4 (en) | 2002-11-06 |
ES2290964T3 (es) | 2008-02-16 |
DE69738077T2 (de) | 2008-05-21 |
DE69738077D1 (de) | 2007-10-11 |
WO1998016628A1 (en) | 1998-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001502537A (ja) | ヒト前立腺ガンの進行の動物モデル | |
US7595431B2 (en) | Mouse models of human prostate cancer | |
WO1998016628A9 (en) | Animal models of human prostate cancer progression | |
Garvin et al. | Disruption of thymocyte development and lymphomagenesis induced by SV4O T-antigen | |
US20020188962A1 (en) | Osteopontin knock-out mouse and methods of use thereof | |
JPH0231632A (ja) | キメラ性非ヒト動物及びそれらの使用 | |
US6365797B1 (en) | Mice models of human prostate cancer progression | |
US7626074B2 (en) | Method of screening candidate drugs for the treatment of leukemia | |
JP2012532604A (ja) | ミミズの生殖巣再生能力を利用した形質転換ミミズの作製方法、これにより作製された形質転換ミミズ、及び形質転換ミミズの体液から組換たんぱく質の生産方法 | |
US20020178460A1 (en) | Transgenic mice expressing fluorescent protein | |
Song et al. | Development of the nude rabbit model | |
Lubaroff et al. | Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL‐2‐activated lymphocytes in SCID mice | |
AU773267B2 (en) | Animal models of human prostate cancer progression | |
CN101993895A (zh) | 高效双启动子PLEGFP-N1-spMyoD1绿色荧光逆转录病毒载体构建及使用方法 | |
KR100666607B1 (ko) | 이종의 cd4 t-세포 생산방법 및 이종의 cd4t-세포를 생산하는 동물모델 | |
JP2004154058A (ja) | ヒト造血器腫瘍の動物モデル | |
O'Neill | HLA-B27 transgenic rats: animal model of human HLA-B27-associated disorders | |
JP2004518405A (ja) | 組換えタンパク質、細胞、および生物を産生するための体細胞クローニング遺伝子移入 | |
Rygaard | Animal models in cancer research | |
Gasser et al. | Andreas Trumpp* ², Yosef Refaeli², Thordur Oskarsson | |
Chen et al. | Jun Song, Mark Hoenerhoff, 2, 4 Dongshan Yang, Ying Yang, 3 Cheng Deng, 3 Luan Wen, Linyuan Ma, Brooke Pallas, Changzhi Zhao, Yui Koike, Tomonari Koike, Patrick Lester, 2 Bo Yang, 3 Jifeng Zhang |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040723 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070723 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071024 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080709 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080821 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101208 |